Controlling the thickness of the atherosclerotic plaque by statin medication

PLoS One. 2020 Oct 13;15(10):e0239953. doi: 10.1371/journal.pone.0239953. eCollection 2020.

Abstract

Atherosclerosis, a chronic inflammatory disorder of the arterial wall, is a complex process whose dynamics are affected by multiple factors. The disease control consists of restraining it by administering statins. Slowing down or halting the plaque growth depends on the patient age at which the statin treatment begins and on the thickness of the intima-media (IMT) at that time. In this paper, we propose a mathematical model to estimate the sets of atherosclerosis states, from which the use of statins can restrain the disease. Our model is control-theoretic, and the estimated sets are the viability kernels, in the parlance of viability theory. To our best knowledge, this way of modelling the atherosclerosis progression is original. We compute two viability kernels, each for a different statin-treatment dose. Each kernel is composed of the vector [age, IMT] from which the disease can be restrained. By extension, the disease can't be restrained from the kernel complements, this being mainly because of the disease and patient-age advancement. The kernels visualise tradeoffs between early and late treatments, which helps the clinician to decide when to start the statin treatment and which statin dose may be sufficient.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Atherosclerosis / drug therapy*
  • Carotid Arteries* / drug effects
  • Carotid Arteries* / pathology
  • Carotid Artery Diseases / drug therapy*
  • Disease Progression
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Models, Theoretical
  • Plaque, Atherosclerotic / drug therapy*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

Grants and funding

This research has been partially supported by the National Science Centre (Poland) Grant No. 2012/07/B/ST6/01537 (DF) and by the statutory funds of Poznan University of Medical Sciences (DF).